Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
Nat Rev Urol. 2021 Sep;18(9):556-571. doi: 10.1038/s41585-021-00488-8. Epub 2021 Jul 8.
Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of the patient's own T cells so that they specifically recognize and destroy tumour cells. Considerable clinical success has been achieved using this technique in patients with lymphoid malignancies, but clinical studies that investigated treating solid tumours using this emerging technology have been disappointing. A number of developments might be able to increase the efficacy of CAR T cell therapy for treatment of prostate cancer, including improved trafficking to the tumour, techniques to overcome the immunosuppressive tumour microenvironment, as well as methods to enhance CAR T cell persistence, specificity and safety. Furthermore, CAR T cell therapy has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy, and could be applied as focal CAR T cell therapy for prostate cancer.
嵌合抗原受体 (CAR) T 细胞免疫疗法涉及对患者自身 T 细胞进行基因修饰，使它们能够特异性识别和破坏肿瘤细胞。这项技术在治疗淋巴恶性肿瘤方面取得了显著的临床成功，但用这种新兴技术治疗实体瘤的临床研究结果却令人失望。有一些新的发展可能会提高 CAR T 细胞疗法治疗前列腺癌的疗效，包括改善 CAR T 细胞向肿瘤的转移、克服肿瘤免疫抑制微环境的技术，以及增强 CAR T 细胞持久性、特异性和安全性的方法。此外，CAR T 细胞疗法有可能与其他治疗方式相结合，如雄激素剥夺疗法、放疗或化疗，并可作为前列腺癌的局部 CAR T 细胞疗法应用。
